01 / DESIGN
What was studied?
STEP 1 enrolled 1,961 adults with obesity or overweight and a related condition, without diabetes. Both groups received lifestyle support over 68 weeks.
02 / FINDINGS
What did the researchers report?
The semaglutide group had greater average weight reduction than the placebo group. Gastrointestinal symptoms were common, and discontinuation because of these symptoms was more frequent with semaglutide.
03 / LIMITS
How should it be interpreted?
This was a defined clinical population receiving a pharmaceutical study product and structured follow-up. Average changes do not predict individual results or establish the properties of research-supply vials.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.